Inhaled insulin: new technology, new possibilities
- 24 May 2006
- journal article
- review article
- Published by Hindawi Limited
- Vol. 60 (6) , 728-734
- https://doi.org/10.1111/j.1742-1241.2006.00976.x
Abstract
The prevalence of diabetes is reaching epidemic proportions with an increasing need for new therapies. Several new therapies are in development and amongst these is inhaled insulin. Inhaled insulin is a novel way of delivering insulin and has been shown to have an efficacy comparable to subcutaneous insulin in patients with both type 1 and type 2 diabetes. Several inhaled insulin delivery systems are currently in development and the first of these, Exubera has recently been granted license in Europe and in the USA. In this article we review the efficacy and safety profile of Exubera and discuss its potential place in the management of diabetes.Keywords
This publication has 29 references indexed in Scilit:
- Poor Control of Risk Factors for Vascular Disease Among Adults With Previously Diagnosed DiabetesJAMA, 2004
- Clinical Pharmacokinetics and Pharmacodynamics of Inhaled InsulinClinical Pharmacokinetics, 2004
- New horizons — alternative routes for insulin therapyNature Reviews Drug Discovery, 2002
- Sulfonylurea InadequacyDiabetes Care, 2002
- Injection related anxiety in insulin-treated diabetesDiabetes Research and Clinical Practice, 1999
- Inhaled InsulinDiabetes Technology & Therapeutics, 1999
- Novel Methods of Insulin Delivery: An UpdateCritical Reviews in Therapeutic Drug Carrier Systems, 1998
- NIDDM Patients' Fears and Hopes About Insulin Therapy: The basis of patient reluctanceDiabetes Care, 1997
- Time-action Profile of Inhaled InsulinDiabetic Medicine, 1997
- Determinants of drug and polypeptide bioavailability from aerosols delivered to the lungAdvanced Drug Delivery Reviews, 1990